RTW Biotech Opportunities (LON:RTW) Shares Up 1.7% – Should You Buy?

RTW Biotech Opportunities (LON:RTW) shot up 1.7% on Tuesday . The stock traded as high as GBX 2.38 and last traded at GBX 2.36. 639,309 shares were traded during trading, a decline of 6% from the average session volume of 683,088 shares. The stock had previously closed at GBX 2.32.

RTW Biotech Opportunities Stock Performance

The company has a debt-to-equity ratio of 20.05, a quick ratio of 0.81 and a current ratio of 0.15. The company has a market cap of £7.62 million, a P/E ratio of 0.04 and a beta of 0.77. The firm has a 50 day moving average price of GBX 2.47 and a 200-day moving average price of GBX 2.26.

RTW Biotech Opportunities Company Profile

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Bio invests in companies developing next-generation therapies and technologies that can significantly improve patients’ lives. RTW Bio is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.